Ranitidine Bismuth Citrate Tablet
Tripotassium Bismuth Dicitrate · Ranitidine Hydrochloride +1 more
Prescription medication · Combination
Kujoo Pharmaceutical Co., Ltd.
MFDS item code 201906839 · Approved 2019.09.26
This product's status changed to Approval withdrawn on 2023.06.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of acid-related disorders (gastric ulcer, gastritis, etc.); prevention of Mendelson syndrome during anesthesia
This medication is used to treat gastric and duodenal ulcers, gastritis, Zollinger-Ellison syndrome, and gastroesophageal reflux disease. It is also effective for ulcers that may occur after surgery and for gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs). It is sometimes administered to prevent Mendelson's syndrome before anesthesia. It is a medication that helps improve various digestive diseases.
○ Adults The usual dose is 1 tablet orally twice daily, in the morning and at bedtime, regardless of meals. 1) Gastric and duodenal ulcers Administer 1 tablet twice daily or 2 tablets once daily at bedtime. A higher cure rate may be achieved, particularly in patients with duodenal ulcers, by administering 2 tablets twice daily, in the morning and at bedtime. The dose is the same when used for ulcers caused by nonsteroidal anti-inflammatory drugs or as concomitant therapy to prevent gastric or duodenal ulcers during long-term treatment with nonsteroidal anti-inflammatory drugs. Conditions caused by nonsteroidal anti-inflammatory drugs are usually cured within 4 weeks, and ulcers are usually cured within 8 weeks, although healing may occasionally take longer in some patients. For patients with recurrent ulcers who responded well to short-term treatment with this medicine, administer 1 tablet once daily at bedtime as maintenance therapy. 2) Reflux esophagitis Administer 1 tablet twice daily or 2 tablets once daily at bedtime for 8 weeks. For patients with severe reflux esophagitis, the dose may be increased to 2 tablets 4 times daily. 3) Zollinger-Ellison syndrome Initiate treatment with 1 tablet 3 times daily as the initial dose, and increase the dose as needed. In severe cases, up to 6 g of ranitidine per day may be administered as directed by a physician. 4) Upper gastrointestinal bleeding due to peptic ulcers, acute stress ulcers, and acute gastric mucosal lesions Once oral administration is possible, switch from injection to oral administration and give 1 tablet twice daily. 5) Premedication for anesthesia (prevention of Mendelson's syndrome) Administer 1 tablet 2 hours before induction of anesthesia. It is preferable to also administer 1 tablet on the night before surgery.
This medication should not be used in patients undergoing dialysis treatment. Patients who have had an allergic reaction to this drug or its components should not be administered this medication. Patients with a history of acute porphyria should not use this drug as it may trigger seizures. It is safer not to use this drug in patients with poor renal function. Patients who have undergone upper gastrointestinal surgery are also advised not to receive this medication. Women who are pregnant or may become pregnant should not take this medication. This medication should not be given to premature infants or newborns. Patients on a potassium-restricted diet should preferably avoid this drug. Patients with impaired liver function or a history of drug allergies should use this medication with caution. Elderly patients or those with renal function issues should also take it with care. If used in conjunction with non-steroidal anti-inflammatory drugs, particularly in the elderly or those with a history of peptic ulcers, regular monitoring of their condition is necessary. This medication can mask symptoms of gastric cancer, so patients with gastric ulcers or those over middle age who have new or changed dyspeptic symptoms should check for malignancy prior to treatment. Patients with Helicobacter pylori-induced gastric or duodenal ulcers require eradication therapy. Severely ill patients in intensive care units should be cautious as this medication may lead to the formation of bezoars. Patients with hypophosphatemia should be careful since some components of this drug may interfere with phosphate absorption. Patients with swallowing difficulties may also experience respiratory complications after taking this medication, so caution is needed. While taking this medication, serious allergic reactions such as anaphylactic shock may rarely occur, so if symptoms arise, use should be immediately discontinued, and medical assistance should be sought. Allergic symptoms such as skin rash, urticaria, angioedema, fever, bronchospasm, hypotension, chest pain, etc., may also rarely appear, and if such symptoms occur, the medication should be stopped. Blood-related abnormalities including leukopenia, thrombocytopenia, and increased serum enzymes may occur rarely, and if symptoms are severe, administration should be stopped immediately. Liver function abnormalities may also occur rarely, so if jaundice or hepatitis symptoms appear, the medication should be discontinued. Irregular heartbeat or vasculitis has also been reported very rarely, so caution is needed if abnormalities arise. Gastrointestinal symptoms such as nausea, vomiting, constipation, diarrhea, and abdominal pain may appear infrequently, and stool may become black, but this does not require special treatment. Neurological symptoms such as dizziness, drowsiness, confusion, spasms, insomnia, headaches may rarely appear, so if symptoms occur, consultation with a healthcare professional is necessary. Muscle pain or joint pain may appear infrequently, and in severe cases, the medication should be discontinued. Skin rashes or hair loss have also been reported infrequently. This medication is best not taken for an extended period, and it should be used at the minimum effective dose while closely monitoring the course of treatment. If no effect is seen, switching to another medication is recommended. Elderly patients, those with chronic lung diseases, diabetes, and weakened immune systems may have an increased risk of pneumonia while taking this medication, so caution is advised. If dizziness or drowsiness occurs after taking it, it is advisable to avoid driving or operating hazardous machinery. This medication may interact with other drugs, so patients taking other medications should inform their healthcare provider. Particularly, when used with medications that affect blood coagulation, regular blood tests should be conducted to monitor the condition. Additionally, when taken with certain antibiotics or cardiac medications, it may affect drug absorption, so it is preferable to space out doses adequately. It is safe for women who are pregnant or nursing to avoid taking this medication. Safety for pediatric use has not been established, so it is preferable not to use it in children. In case of overdose, emergency treatment such as vomiting or gastric lavage may be performed, and if necessary, blood dialysis can be used for removal. This medication may reduce gastric acid secretion, which can promote bacterial proliferation in the gastrointestinal tract, so regular check-ups including ocular examinations may be required for long-term use.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius (room temperature).
Green rectangular film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Tripotassium Bismuth Dicitrate · Ranitidine Hydrochloride +1 more
Prescription medication · Combination
Kujoo Pharmaceutical Co., Ltd.
CombinationRanitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
Nexpharm Korea Co., Ltd.
CombinationRanitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
HUONS BioScience Co., Ltd.
CombinationRanitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationRanitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
Ranitidine Hydrochloride 84mg · Sucralfate Hydrate 300mg +1 more
Tablet · Prescription medication · Combination
Korea Pavise Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 84mg · Sucralfate Hydrate 300mg +1 more
Tablet · Prescription medication · Combination
Kwangdong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.